According to research, Tesamorelin, known under the name Egrifta is a synthetic version of growth hormone releasing hormone. Reports show that it is made of 44 amino acids and has a trans-3-hexenoic acid group.
| Application: | Aid in weight loss |
| CAS: | 218949-48-5 |
| Molecular Weight: | 5135.9 Daltons |
| Chemical Formula: | C221H366N72O67S |
| Chemical Name: | |
| Synonyms: | Egrifta |
| Storage: | Minimize open air exposure, store in a cool dry place. |
| Stability: | 2 years |
| Purity: | 95% |
| Solubility: | Soluble to water at rate of 1mg/ml |
| Physical Form: | fine powder in glass vial |
| Specifications: | 10mg vial |
| Terms: | The products we offer are intended for laboratory research use only. You will need to purchase Bacteriostatic water separately. |
Tesamorelin, classified as a growth hormone-releasing hormone (GHRH), is a synthetic peptide primarily employed in scientific research. It holds considerable interest across multiple disciplines including endocrinology, neuroscience, and pharmacology. Tesamorelin operates as a mimetic of the endogenous GHRH, acting on the hypothalamic-pituitary axis to regulate the release of growth hormone (GH) from the pituitary gland. While it shows promise for potential therapeutic applications, it is important to emphasize that tesamorelin is strictly intended for laboratory investigations.
Structure and Amino Acid Breakdown of Tesamorelin
Tesamorelin’s molecular structure consists of a precisely arranged chain of 44 amino acid residues. This chain is meticulously crafted to optimize its biological activity and pharmacological properties. Among these amino acids, certain residues play pivotal roles in tesamorelin’s function. For instance, residues like alanine, glutamine, and serine are strategically positioned within the peptide sequence to enhance its stability and binding affinity to specific receptors.
Through detailed analysis of the amino acid composition and spatial arrangement within tesamorelin, researchers can decipher how these molecular constituents contribute to its ability to stimulate the release of GH. Understanding the intricacies of tesamorelin’s structure provides valuable insights into its mechanisms of action and potential applications in scientific research.
Mechanism of Action of Tesamorelin
The mechanism of action of tesamorelin revolves around its interaction with specific receptors located on the surface of somatotroph cells within the anterior pituitary gland. Upon administration, tesamorelin binds to these receptors, triggering a series of intracellular signaling cascades. These signaling pathways involve activation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) pathways, ultimately leading to the transcription and synthesis of GH mRNA and subsequent secretion of GH into the bloodstream.
Importantly, tesamorelin exhibits a high degree of selectivity towards GH release, minimizing non-specific effects and off-target interactions. This specificity enhances its utility as a precise research tool for investigating the complex mechanisms underlying hormone regulation and homeostasis within the body.
Long Term Tesamorelin Use For HIV Abdominal Fat Accumulation
The study aimed to evaluate the long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with central fat accumulation. Initially, patients were randomized to receive either tesamorelin or placebo for 26 weeks. After this period, patients on tesamorelin either continued treatment or switched to placebo, while those on placebo began tesamorelin therapy for an additional 26 weeks. Safety assessments included monitoring adverse events and glucose parameters.
Tesamorelin was well tolerated throughout the study, with adverse event rates comparable to the initial phase. Glucose levels remained stable over 52 weeks, and reductions in visceral adipose tissue and triglycerides were sustained. Total cholesterol showed sustained improvements, while high-density lipoprotein decreased slightly. Notably, upon discontinuation of tesamorelin, VAT reaccumulated. [3]
In conclusion, treatment with tesamorelin demonstrated long-term safety and sustained reductions in VAT and triglycerides over 52 weeks without adverse effects on glucose levels. However, the beneficial effects on VAT were not maintained after treatment cessation, indicating the need for continued therapy to sustain improvements in body composition among HIV patients with central fat accumulation. [3]
Study Of Tesamorelin Treatments On Non-Alcoholic Fatty Liver Disease In HIV
The study aimed to evaluate the effects of tesamorelin on liver fat and histology in individuals with HIV and non-alcoholic fatty liver disease (NAFLD), a significant comorbidity in this population without established pharmacological treatments. Conducted in the USA, this randomized, double-blind, multicenter trial enrolled individuals with HIV and a hepatic fat fraction (HFF) of 5% or more by proton magnetic resonance spectroscopy. Participants were randomly assigned to receive either tesamorelin once daily or placebo for 12 months, followed by a 6-month open-label phase with all participants receiving tesamorelin.
The primary endpoint was the change in HFF between baseline and 12 months, with glucose levels monitored as the primary safety endpoint. Of the 61 enrolled patients, 30 received tesamorelin and 30 received placebo.
The tesamorelin group exhibited a greater reduction in HFF compared to the placebo group, with a relative reduction of -37% from baseline after 12 months. Notably, 35% of individuals in the tesamorelin group achieved an HFF of less than 5%, compared to 4% in the placebo group. Changes in fasting glucose and glycated hemoglobin did not differ significantly between the groups at 12 months. [5]
While individuals in the tesamorelin group experienced more localized injection site complaints, none were deemed serious. The findings suggest that tesamorelin may be effective in reducing liver fat in individuals with HIV and NAFLD, with manageable side effects, thus holding promise as a potential treatment option for this population. [5]
Therapeutic Implications of Tesamorelin in Animal Research
In animal research, tesamorelin holds promise for various therapeutic applications primarily focused on its ability to modulate growth hormone (GH) levels and influence physiological processes. Studies utilizing animal models have explored the potential therapeutic implications of tesamorelin in the following contexts:
- Metabolic Disorders: Animal studies have investigated the effects of tesamorelin on metabolic disorders such as obesity and insulin resistance. By stimulating GH release, tesamorelin may promote lipolysis, thereby reducing adiposity and improving metabolic parameters in animal models of obesity and metabolic syndrome.
- Muscle Wasting and Sarcopenia: Tesamorelin’s ability to enhance GH secretion has been explored in animal models of muscle wasting and sarcopenia. Research suggests that tesamorelin administration may mitigate muscle loss and improve muscle mass and function in aging or disease-related conditions characterized by muscle wasting.
- Bone Health: Tesamorelin has been studied in animal models to assess its potential effects on bone metabolism and bone health. GH plays a crucial role in bone homeostasis, and tesamorelin-induced GH release may have implications for bone density and skeletal integrity in certain pathological conditions associated with bone loss.
- Cognitive Function: Animal research has investigated the impact of tesamorelin on cognitive function and neuroprotection. GH has been implicated in various aspects of brain function, including neuronal growth and synaptic plasticity. Tesamorelin administration in animal models has shown potential benefits in cognitive tasks and neuroprotection against certain neurodegenerative conditions.
- Cardiovascular Health: Studies in animal models have explored the cardiovascular effects of tesamorelin, particularly its influence on cardiac function and vascular health. Tesamorelin-induced GH release may exert cardioprotective effects, including improved cardiac contractility, vascular endothelial function, and lipid metabolism in preclinical models of cardiovascular disease.
Overall, while the therapeutic implications of tesamorelin in animal research are promising, further preclinical investigations are warranted to elucidate its full potential and assess safety profiles before considering clinical translation.
*Disclaimer: The Tesamorelin currently listed on this site is for research use only. Not for human consumption. This product is not a drug, supplement, food or cosmetic and it may not be misused, sold, labeled or branded as such.
Research:
[1] https://link.springer.com/article/10.2165/11202240-000000000-00000
[5] https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(19)30338-8/fulltext
| Weight | .25 oz |
|---|---|
| Dimensions | 1 × 1 × 1 in |
Michael White –
This stuff torches fat tight off you. Caloric deficit and heavy training yielded best results I could have hoped for. Can’t wait to try some other peptides